Alexion Pharmaceuticals (ALXN) stock price, revenue, and financials

Alexion Pharmaceuticals market cap is $24 b, and annual revenue was $4.13 b in FY 2018

$24 B

ALXN Mkt cap, 15-Nov-2019

$1.3 B

Alexion Pharmaceuticals Revenue Q3, 2019
Alexion Pharmaceuticals Gross profit (Q3, 2019)1.2 B
Alexion Pharmaceuticals Gross profit margin (Q3, 2019), %92.5%
Alexion Pharmaceuticals Net income (Q3, 2019)467.6 M
Alexion Pharmaceuticals Cash, 30-Sep-20192.2 B
Alexion Pharmaceuticals EV24.5 B

Alexion Pharmaceuticals Revenue

Alexion Pharmaceuticals revenue was $4.13 b in FY, 2018

Embed Graph

Alexion Pharmaceuticals Income Statement

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

125.8m141.6m166.1m204.0m244.7m274.7m294.1m338.9m370.1m400.4m566.6m512.5m555.1m600.3m636.2m666.6m701.0m753.1m799.1m870.0m912.0m859.0m930.9m1.0b1.0b1.1b1.2b1.3b

Cost of goods sold

13.7m16.5m19.2m23.4m28.3m31.6m20.2m35.3m39.4m51.4m32.9m39.6m51.9m69.4m52.0m54.1m59.0m60.6m71.1m69.0m84.0m157.0m91.6m95.3m90.6m85.8m99.2m95.2m

Gross profit

112.1m125.1m146.9m180.7m216.5m243.1m273.9m303.7m330.7m349.0m533.7m472.9m503.3m530.9m584.2m612.6m642.1m692.5m728.0m801.0m828.0m702.0m839.3m949.7m935.9m1.1b1.1b1.2b

Gross profit Margin, %

89%88%88%89%88%88%93%90%89%87%94%92%91%88%92%92%92%92%91%92%91%82%90%91%91%92%92%92%

R&D expense

23.7m25.2m30.8m36.6m45.4m59.6m54.3m74.5m68.6m88.2m191.5m92.6m100.7m221.1m131.7m165.7m176.3m179.3m195.7m219.0m199.0m195.0m176.6m173.4m174.8m195.9m187.6m232.9m

General and administrative expense

56.1m57.2m65.9m77.6m87.2m94.9m90.0m108.8m123.2m122.9m129.3m159.5m157.7m187.1m221.4m212.5m232.6m231.8m230.1m262.0m265.0m271.0m277.3m258.7m281.5m299.3m299.3m

Operating expense total

79.8m82.4m106.7m114.5m146.4m159.4m171.6m186.7m193.0m213.8m324.2m254.0m266.6m427.2m403.1m458.0m476.2m497.8m548.7m589.0m602.0m622.0m176.6m1.3b577.3m486.5m571.5m532.5m

Depreciation and amortization

80.1m80.0m80.0m80.0m

EBIT

32.3m42.7m40.2m66.2m70.0m83.7m142.7m117.0m137.7m135.3m209.5m218.8m236.7m103.7m181.1m154.6m165.8m194.7m179.3m212.0m226.0m80.0m(400.1m)358.6m532.6m

EBIT margin, %

26%30%24%32%29%30%49%35%37%34%37%43%43%17%28%23%24%26%22%24%25%9%(38%)35%44%

Interest expense

158.0k162.0k198.0k204.0k2.3m2.1m1.9m1.2m1.1m24.0m24.0m

Interest income

336.0k483.0k396.0k523.0k273.0k282.0k317.0k437.0k718.0k638.0k2.2m1.7m2.3m2.9m2.2m2.0m1.6m1.9m4.6m4.0m4.0m5.0m105.8m7.7m5.9m42.5m

Investment income

(14.9m)

Pre tax profit

32.1m42.6m40.8m65.7m67.8m81.7m140.8m116.7m137.3m134.3m211.9m218.6m236.2m106.9m177.3m139.4m143.6m170.0m158.1m194.0m206.0m58.0m351.6m(418.6m)342.1m541.8m499.5m535.5m

Income tax expense

10.3m14.7m14.0m107.0k22.4m45.5m48.6m34.5m41.4m40.5m52.6m52.2m58.5m15.6m7.1m323.1m51.4m55.0m63.8m24.0m41.0m(20.0m)102.5m38.8m11.2m(46.1m)39.7m67.9m

Net Income

21.8m27.9m26.8m65.6m45.4m36.3m92.2m82.2m95.9m93.8m159.4m166.5m177.7m91.3m170.2m(183.8m)92.2m114.9m94.3m170.0m165.0m78.0m249.1m(457.4m)330.9m587.9m459.8m467.6m

Alexion Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

212.1m210.0m289.4m347.9m438.2m359.4m806.2m905.5m1.0b936.5m910.4m528.3m612.0m752.2m916.8m1.3b1.2b710.2m597.6m762.0m713.0m542.0m550.0m511.8m727.5m1.2b1.5b2.0b2.2b

Accounts Receivable

127.0m154.1m200.7m212.7m221.3m267.4m282.7m311.4m323.9m355.3m405.0m429.0m440.7m436.5m479.9m535.8m512.3m586.2m609.3m676.8m660.0m710.0m705.0m776.7m853.7m910.2m1.0b1.1b1.1b

Prepaid Expenses

41.4m25.5m24.9m23.6m52.6m73.2m74.0m84.3m81.3m71.4m78.8m87.4m111.1m147.3m273.5m268.7m272.9m219.7m242.0m241.8m215.0m225.0m207.0m327.9m342.2m370.4m497.0m460.7m432.5m

Inventories

57.7m60.4m74.4m75.2m78.3m92.9m94.1m90.0m101.9m112.6m105.2m126.2m144.9m140.0m174.5m234.3m236.5m294.0m329.8m363.1m396.0m410.0m441.0m456.5m463.2m432.7m482.2m494.6m576.7m

Current Assets

491.8m558.2m669.2m700.4m817.4m811.9m1.3b1.4b1.6b1.7b1.9b2.2b2.3b2.6b2.9b2.5b2.5b2.1b2.4b2.6b2.7b2.8b2.9b3.2b2.8b3.2b3.7b4.2b4.3b

PP&E

161.9m162.1m160.6m163.8m164.2m165.8m164.6m165.0m165.0m173.7m178.8m218.1m273.3m328.5m440.5m555.4m618.7m749.3m825.3m931.1m1.1b1.2b1.4b1.4b1.4b1.4b1.1b1.1b

Goodwill

20.0m20.0m79.1m80.0m80.0m264.1m255.4m253.8m254.1m254.1m254.1m254.1m254.1m254.1m254.1m5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b5.0b

Total Assets

889.6m942.3m1.2b1.2b1.3b2.0b2.5b2.5b2.7b2.8b3.0b3.4b3.6b3.9b4.4b13.2b13.2b12.8b13.0b13.3b13.4b13.5b13.6b13.8b13.5b13.8b14.0b14.6b

Accounts Payable

11.0m13.3m9.0m13.4m14.4m16.0m23.8m22.0m25.6m25.6m24.4m35.3m36.1m23.2m52.9m47.0m47.0m42.9m29.0m44.8m61.0m51.0m35.0m57.1m58.8m52.2m669.8m728.7m868.2m

Short-term debt

245.0k939.0k1.1m964.0k712.0k108.0m48.0m48.0m48.0m48.0m48.0m48.0m48.0m48.0m45.5m131.3m175.0m35.4m79.1m322.9m167.0m167.0m167.0m167.5m278.5m311.2m126.5m126.6m126.6m

Current Liabilities

89.2m117.7m217.2m187.8m211.2m353.7m375.2m361.9m295.7m303.0m395.5m396.8m417.7m502.5m580.4m769.2m766.9m603.6m658.5m1.0b837.0m856.0m972.0m942.0m1.0b1.0b943.8m1.0b1.1b

Long-term debt

381.0k306.0k462.0k378.0k286.0k247.0m180.0m113.0m101.0m89.0m77.0m45.5m33.5m21.5m3.4b3.3b3.2b3.2b2.9b2.8b2.8b2.8b2.7b2.6b2.5b2.6b2.6b2.6b

Total Debt

626.0k1.2m1.5m1.3m998.0k355.0m228.0m161.0m149.0m137.0m48.0m48.0m48.0m48.0m45.5m131.3m175.0m35.4m79.1m322.9m167.0m167.0m167.0m2.8b2.8b2.8b2.7b2.7b2.7b

Total Liabilities

97.4m130.4m253.2m226.1m249.3m804.2m707.9m633.2m595.8m603.7m695.0m678.7m672.2m767.8m898.0m4.6b4.9b4.7b4.8b4.8b4.6b4.6b4.7b4.7b4.7b4.7b4.3b4.4b4.4b

Common Stock

5.0k5.0k6.0k18.0k19.0k19.0k19.0k19.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k23.0k23.0k23.0k23.0k23.0k

Preferred Stock

Additional Paid-in Capital

1.1b1.1b1.2b1.2b1.2b1.3b1.8b1.8b1.9b2.0b2.0b2.3b2.5b2.6b2.7b7.7b7.6b7.8b7.9b7.9b8.1b8.1b8.2b8.4b8.4b8.5b8.6b

Retained Earnings

(358.3m)(330.4m)(277.1m)(242.4m)(176.8m)(83.2m)(46.9m)45.2m208.4m304.3m398.1m538.5m704.9m882.7m1.1b1.3b1.1b1.3b1.4b1.7b2.0b2.1b2.2b2.5b2.0b2.4b2.8b3.3b3.8b

Total Equity

792.2m811.8m901.4m953.5m1.1b1.2b1.7b1.9b2.1b2.2b2.4b2.7b2.9b3.1b3.5b8.6b8.3b8.1b8.2b8.5b8.9b8.9b8.9b9.1b8.8b9.2b9.7b10.2b10.4b

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.1 x1.2 x1.3 x1.2 x1.2 x1.7 x1.4 x1.3 x1.3 x1.3 x1.3 x1.3 x1.2 x1.2 x1.3 x1.5 x1.6 x1.6 x1.6 x1.6 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.4 x1.4 x

Alexion Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

42.7m70.6m26.8m61.6m127.1m45.4m81.7m173.9m82.2m178.1m271.9m159.4m325.8m503.6m91.3m261.5m77.8m92.2m207.1m306.6m170.0m335.0m413.0m249.1m(208.3m)122.6m587.9m1.0b1.5b

Depreciation and Amortization

7.8m11.9m4.3m8.7m13.2m5.9m11.4m17.6m6.3m13.0m20.2m9.3m19.0m28.4m10.6m23.1m72.9m96.8m194.6m295.3m99.0m201.0m311.0m101.5m202.0m306.9m97.2m193.7m286.2m

Accounts Receivable

24.1m42.2m(26.6m)(35.8m)(52.3m)(20.2m)(41.7m)(65.3m)(26.2m)(55.2m)(98.4m)63.0k(9.2m)(22.7m)(58.9m)(109.0m)(91.0m)(37.3m)(65.2m)(129.9m)(3.0m)(46.0m)(35.0m)(42.7m)(137.0m)(197.4m)(95.3m)(196.4m)(199.1m)

Inventories

13.8m14.2m(10.4m)(9.5m)(10.9m)(9.7m)(9.3m)(3.5m)(5.5m)(14.4m)(5.0m)(20.9m)(35.0m)(26.2m)2.6m4.7m(7.4m)(3.8m)(39.0m)(72.2m)(19.0m)(33.0m)(69.0m)3.9m(4.1m)26.7m(11.2m)(105.9m)

Accounts Payable

6.4m24.9m5.4m36.9m54.5m(2.8m)76.9m59.9m(62.3m)(53.1m)4.0m(60.7m)78.3m166.5m(13.7m)(10.8m)(147.1m)(42.5m)(6.7m)92.8m39.0m61.0m102.0m(73.7m)(130.6m)(167.3m)23.6m207.1m

Cash From Operating Activities

67.0m109.9m24.4m103.0m179.3m62.8m164.3m305.7m46.5m144.2m288.5m(31.1m)75.1m356.6m23.0m261.3m484.3m168.0m411.9m703.3m308.0m588.0m858.0m299.3m(44.5m)342.6m429.9m968.3m1.6b

Purchases of PP&E

(5.5m)(8.9m)(2.2m)(9.8m)(15.2m)(3.8m)(8.0m)(14.3m)(5.5m)(14.0m)(20.6m)(17.7m)(61.2m)(83.9m)(57.1m)(130.2m)(206.2m)(64.2m)(131.0m)(226.0m)(75.0m)(175.0m)(269.0m)(129.4m)(170.6m)(36.0m)(82.8m)(124.7m)

Cash From Investing Activities

(23.9m)(79.3m)(73.0m)(42.0m)(34.4m)(609.2m)(613.8m)(620.0m)(5.6m)(197.5m)(413.9m)(90.2m)(90.1m)(165.7m)(48.4m)(3.2b)(3.4b)(5.7m)(336.3m)(401.6m)(495.0m)(748.0m)(919.0m)(254.7m)313.6m418.3m2.9m(38.1m)(46.6m)

Short-term Borrowings

(115.0m)(115.0m)(200.0m)(200.0m)(250.0m)

Long-term Borrowings

(305.0k)(379.0k)(92.0k)(290.0k)(640.0k)(91.0k)(12.0m)(79.0m)(12.0m)(24.0m)(19.5m)(31.5m)(43.5m)(12.0m)(57.5m)(57.5m)(175.0m)(175.0m)(175.0m)(44.0m)(96.0m)(141.0m)(43.8m)(293.8m)(293.8m)(3.7m)

Cash From Financing Activities

14.2m23.0m69.9m17.8m26.2m364.6m715.6m678.9m(4.3m)2.7m47.1m119.2m96.6m37.2m5.1m3.4b3.2b(466.3m)(490.3m)(552.5m)(69.0m)(276.0m)(371.0m)(123.5m)(116.5m)(105.5m)(252.4m)(313.5m)(679.4m)

Net Change in Cash

54.9m52.8m22.3m80.7m171.0m(181.5m)265.3m364.7m33.5m(53.0m)(79.1m)(1.6m)82.2m222.3m(27.2m)378.1m219.3m(299.9m)(412.6m)(248.1m)(253.0m)(424.0m)(416.0m)(72.6m)146.5m644.8m179.0m617.4m835.7m

Alexion Pharmaceuticals Ratios

USDY, 2019

EV/CFO

15.6 x